Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

• Published in: Journal of neurology, neurosurgery and psychiatry Vol. 84; no. 11; pp. 1186 - 1191
• Main Authors: Weinstock-Guttman, Bianca, Zivadinov, Robert, Horakova, Dana, Havrdova, Eva, Qu, Jun, Shyh, Grace, Lakota, Elizabeth, O'Connor, Kerri, Badgett, Darlene, Tamaño-Blanco, Miriam, Tyblova, Michaela, Hussein, Sara, Bergsland, Niels, Willis, Laura, Krasensky, Jan, Vaneckova, Manuela, Seidl, Zdenek, Ramanathan, Murali
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.11.2013
• Subjects: Adjuvants, Immunologic - therapeutic use; Adult; Body Mass Index; Brain - drug effects; Brain - pathology; Calcifediol - blood; Cholesterol - blood; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Clinical Neurology; Cohort Studies; Czech Republic; Demyelinating Diseases - blood; Demyelinating Diseases - drug therapy; Early Medical Intervention; Female; Humans; Injections, Intramuscular; Interferon beta-1a; Interferon-beta - therapeutic use; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Mri; Multiple Sclerosis; Multiple Sclerosis - blood; Multiple Sclerosis - diagnosis; Multiple Sclerosis - drug therapy; Neurobiology; Neuroradiology; Prospective Studies; Smoking - adverse effects; Smoking - blood; Thyrotropin - blood; Thyroxine - blood; Young Adult; Czech Republic; Multiple Sclerosis; Clinical Neurology; Mri; Neuroradiology; Neurobiology

Objectives To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. Methods High density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC...